Michael Halassa’s Blog
Early Experience with Cobenfy: A Promising Schizophrenia Treatment for Specific Cases
Discover how Cobenfy (xanomeline/trospium), a novel muscarinic agonist, is transforming schizophrenia treatment for resistant cases, improving negative symptoms, and offering hope for patients
GABAergic Targeting in Psychotic Disorders: A Forgotten Piece of the Puzzle?
Michael Halassa discussed the overlooked potential for GABAergic systems in schizophrenia treatment. Both existing and upcoming medications are discussed.
Negative Symptoms in Schizophrenia: An unmet need
Michael Halassa outlines the challenges in diagnosing schizophrenia when the most prominent attribute is negative symptoms.
Paper Alert! Revealing the Neural Basis of Executive Dysfunction in Schizophrenia
I would like to highlight a new paper that we published in collaboration with Neil Woodward’s lab at Vanderbilt, co-lead by research professors Anna Huang (Vanderbilt) and Ralf Wimmer (Tufts), with contributions from postdoctoral fellow Norman Lam and MSTP student...
KarXT: A New Medication for treating Schizophrenia
I recently participated in the 7th Neuropsychiatric Drug Development Summit in Boston, which was a refreshing experience. Steve Moss and I co-led a workshop focused on the integration of systems and cellular neuroscience as it relates to drug discovery (more on that...
A Blueprint for Algorithmic Psychiatry: Revolutionizing Mental Health Treatment
Mental health care has long been dominated by the Diagnostic and Statistical Manual of Mental Disorders (DSM), a classification system that guides clinicians in diagnosing and treating psychiatric illnesses. While the DSM has provided a standardized approach to...